Blackhawk’s MindBio Therapeutics Ahead of Schedule to Complete Phase 1 Clinical Trial Microdosing of Psychedelic
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001 VANCOUVER,
Blackhawk’s MindBio Therapeutics to Develop Psychedelic Medicine in Microdoses Ready for Commercial Use to Treat
MindBio Therapeutics is aiming to develop a “smart drug delivery technology” that can use patient
Morning Glory Has A Hell Of A Psychedelic Story This common flower can make you
Mycrodose Therapeutics Receives DEA License to Research Four Psychedelics Mycrodose Therapeutics is pleased to announce that
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel HaluGen Life Sciences expanded its psychedelic DNA
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD MindMed (MNMD) is
PharmaTher Announces Positive Research Results for LSD Microneedle Patch Delivering LSD via microneedle patch unlocks
BetterLife Obtains Positive TD-0148A Data in Preclinical Models of Depression BetterLife Pharma (BETR) found that
MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures MindMed (MNMD) launched
Blackhawk Growth’s MindBio Therapeutics Advances Microdosing Clinical Trial to 59 Patients Vancouver, British Columbia – TheNewswire
Blackhawk Growth’s MindBio Therapeutics Completes Safety Milestone In Its Phase 1 Clinical Trials Vancouver, British
PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics Completing IND-enabling studies with
Blackhawk Growth’s MindBio Therapeutics Looks to Expand Microdosing Clinical Trials Vancouver, British Columbia – November
Delic Labs Applies for Dealers License to Commercialize Psychedelics Research, Health Exemption to Test MDMA
Blackhawk Growth’s MindBio Therapeutics Successfully Progressed to the Second Half of their Phase 1 Microdosing
MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration A new study found
Blackhawk Growth’s MindBio Therapeutics Plans to Commercialize Intellectual Property Generated from the University of Auckland’s
Blackhawk Growth Subsidiary, MindBio Therapeutics, Accelerates Phase 1 & Phase 2 Microdosing Clinical Trials Vancouver,
Blue Sun Mycology Group Announces Filing of 2 US Patents for Methods Related to Inventing
Blackhawk Growth to Complete Investment in Psychedelic and Wellness Company MindBio Therapeutics Pty Ltd. Vancouver,
